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Could HIF-1α be a novel biomarker for the clinical course and treatment of pulmonary
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Background/aim: Pulmonary embolism (PE) is associated with high morbidity and mortality rates if not diagnosed and treated rapidly.
The aim of our study was to investigate the relationship between levels of hypoxia-induced factor-1 alpha (HIF-1α) and clinical course
and prognosis in patients with intermediate low-risk, intermediate high-risk, and high-risk PE.
Materials and methods: The study included 240 subjects in 4 groups: a healthy control group (n = 60, mean age = 60 ± 15.2, female/male
= 30/30 ), intermediate low-risk PE group (n = 60, mean age = 60 ± 12,5, female/male = 27/33), intermediate high-risk PE group (n =
60, mean age = 61,4 ± 14,8, female/male = 36/24), and high-risk PE group (n = 60, mean age = 62,3 ± 15, female/male = 33/27). Plasma
HIF-1α levels were measured using commercial enzyme-linked immunosorbent assay (ELISA) kit.
Results: Comparison of HIF-1α levels revealed a statistically significant difference between the groups in proportion to clinical scoring
(P = 0.001 for all). Comparison of initial HIF-1α and troponin levels in intermediate high-risk PE patients given thrombolytic therapy
and those treated with enoxaparin sodium showed that HIF-1α levels were significantly higher in the group that received thrombolytic
therapy (P = 0.001), while there was no difference in troponin levels (P = 0.146).
Conclusion: HIF-1α can be used in the PE clinical risk stratification and monitoring of PE and may also serve as a valuable early
indicator in intermediate high-risk PE, for which early reperfusion therapy is important.
Key words: HIF-1 alpha, pulmonary thromboembolism, hypoxia

1. Introduction
Pulmonary embolism (PE) is usually an early complication
of deep venous thrombosis (DVT) and can cause high
morbidity and mortality rates if not diagnosed and treated
early [1]. The etiology of venous thromboembolism can
involve genetic risk factors as well as acquired risk factors
such as malignancy, pregnancy, oral contraceptive use,
immobility, advanced age, and most importantly, prior
surgery [2].
The commonly used biomarkers troponin, brain
natriuretic peptide (BNP), and N terminal-proBNP (NTproBNP) are used to classify cases of intermediate PE as
low- or high-risk. Right ventricular dilatation due to PE
increases myocardial oxygen demand of the right ventricle.
Microinfarcts resulting in malperfusion in the right
ventricle cause troponin-I release from the myocardium as
an indicator of cell damage, while increased levels of HIF1α and especially VEGF improve the existing pathology [3].

Right ventricle dilation stimulates the myocardial
tissue and vascular bed to synthesize various cytokines,
especially hypoxia inducible factor-1α (HIF-1α), to
regulate oxygenation and promote neovascularization.
HIF-1α induces vascular endothelial growth factor
(VEGF) synthesis to initiate vascularization, while
glutathione peroxidase activity is also increased to prevent
reperfusion injury [4]. VEGF, the main inducer of which is
HIF-1α, plays an important role in thrombus organization
and thrombolysis. In addition to inhibiting platelet
aggregation by causing an increase in nitric oxide levels, it
also promotes the conversion of plasminogen to plasmin
(which is thrombolytic) by increasing serine protease,
urokinase, and tissue plasminogen activity [5,6]. In studies
using rat models of experimental PE, it was determined
that HIF-1α was expressed at a higher level than in the
control group and that this synthesis primarily occurred
in the myocardial tissue and vascular bed [3,7].
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Cardiac biomarkers are still not completely reliable
indicators of disease course; therefore, the aim of the
present study was to determine the relationship between
HIF-1α levels and clinical scoring and course in patients
with PE.
2. Materials and methods
2.1. Study population
The study included 180 PE patients who received inpatient
treatment in the chest diseases department of our hospital
between January and June 2019. Before initiating this
prospective observational study, ethics committee approval
was obtained from the Erzurum Regional Education
Research Hospital (BEAH KAEK 2019/10-104). This
study has been performed in accordance with the ethical
standards laid down in the 1964 Declaration of Helsinki
and its later amendments or comparable ethical standards.
All patients with clinical suspicion of PE (major
risk factors, clinical signs) underwent chest x-ray,
electrocardiogram (ECG), and echocardiographic (ECHO)
evaluation. Those with a high clinical suspicion of PE
underwent CT angiography with a 16-slice multidetector
CT to confirm the diagnosis.
Clinical and laboratory evaluations, including physical
examination, blood pressure, heart rate, complete blood
count, and oxygen saturation, were performed before
and after thrombolytic therapy. ECG examination and
interpretation were done before thrombolytic therapy
only.
High-risk PE (n = 60) was defined as sustained
hypotension (systolic arterial pressure < 90 mmHg or
a drop in systolic arterial pressure of at least 40 mmHg
for at least 15 min) and cardiogenic shock (including an
altered level of consciousness, oliguria, or cool, clammy
extremities). Patients with right ventricular dilatation and
troponin I elevation without hypotension or signs of shock
were classified as intermediate high-risk PE (n = 60), while
those with right ventricular dilatation but no troponin I
elevation were considered intermediate low-risk PE (n
= 60). Sixty healthy volunteers who did not meet any of
the study exclusion criteria and had no history of PE were
selected as the control group.
Patients with high risk PE who were under 65 years
of age were given alteplase as a 10 mg bolus followed by
90 mg infusion over 2 h, while patients over 65 years of
age received half-dose alteplase. Starting immediately
after thrombolytic therapy, enoxaparin sodium was
administered at 12-h intervals. Patients with intermediate
PE received enoxaparin sodium therapy at 12-h intervals.
Eighteen patients in the intermediate high-risk PE patient
group developed hypotension and shock in the first 72 h
and were administered thrombolytic therapy as per the
high risk PE protocol.
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2.2. Exclusion criteria
Patients with history of myocardial infarction and associated
treatment in the past 3 months, severe hypoxic respiratory
failure, PE with concomitant intracranial hemorrhage,
diagnosed malignancy, and known history of right heart
dilation were not included in the study.
2.3. Blood and serum samples
Computed tomography (CT) and ECG were performed and
troponin-I and HIF-1ɑ were assessed before and at the end
of treatment for all patients.
2.4. Measurement of biochemical markers
Venous blood samples were obtained from all patients from
an antecubital vein after at least 15 min of semisupine rest.
All blood samples were collected into tubes containing
ethylenediaminetetraacetic acid (EDTA) to prevent
coagulation. Troponin I concentrations were measured by
chemiluminescent immunoassay using an Immulite 2500
(Siemens Medical Solutions, Erlangen, Germany). HIF1α was measured by enzyme-linked immunosorbent assay
(Elabscience human elisa kit, UK).
2.5. Statistical analysis
The study data were analyzed using SPSS v.20.0 software.
Categorical variables were expressed as number and
percentage; numerical variables were expressed as mean
and standard deviation. The Kolmogorov–Smirnov test
was used to test the normality of data distributions.
Independent-samples t-test was used to compare baseline
HIF-1α and troponin-I levels in intermediate high-risk
PE patients according to treatment status and in surviving
and nonsurviving high-risk PE patients. For all groups,
baseline and 72-h HIF-1α and troponin-I levels, systolic
PAP levels, and hospital length of stay were compared using
the Kruskal–Wallis test, after which significant parameters
were compared with ANOVA with post hoc Tukey test.
ROC curve analysis was used to calculate the sensitivity
and specificity of baseline HIF-1α and troponin-I levels
in patients with and without high-risk PE. Correlations
between baseline HIF-1α and troponin-I levels and systolic
PAP were evaluated using the Pearson correlation analysis.
Results with a P-value of <0.05 were considered statistically
significant.
3. Results
The mean age of the patient groups was 63 ± 14.3 years.
There was no statistically significant difference in mean age
between the study groups. The mean age of the control group
was 60 ± 15.2 years. There was no significant age difference
between patients and controls.
In the high-risk PE group, 9 of the 60 patients died within
the first 72 h and 12 patients died after 72 h. Nine patients
in the intermediate high-risk PE group died after 72 h.
Causes of death in the high-risk PE group were intracerebral
or intraabdominal hemorrhage for 3 patients and hypoxic
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respiratory failure for 18 patients. In the intermediate
high-risk PE group, 3 patients died due to intracerebral
hemorrhage following thrombolytic therapy, while 6 died
after sudden cardiopulmonary arrest.
Results of HIF-1α and troponin levels according to PE
clinical risk scoring are shown in Table 1.
Comparisons of HIF-1α levels between the patient groups
showed that the high-risk PE group had significantly higher
HIF-1α levels compared to the intermediate PE groups (P
= 0.001 for both). When compared with the control group,
the patient groups had significantly higher HIF-1α levels (P
= 0.001 for all), while there were no significant differences
in terms of 72-h HIF-1α levels (P = 0.273 for high-risk PE,
P = 0.98 for both intermediate PE groups). Comparison of
HIF-1α and troponin levels in the intermediate high-risk
PE patients given thrombolytic therapy and those treated
with enoxaparin sodium showed that HIF-1α levels were
significantly higher in the group that received thrombolytic
therapy (P = 0.001), while there was no difference in
troponin levels (P = 0.146) (Table 2).
The 21 patients who died due to high-risk PE had
significantly higher mean HIF-1α level compared to
survivors in the same patient group (P = 0.001). Troponin
levels in the deceased and surviving patients in the highrisk PE group were not statistically significant (P = 0.72)
(Table 2). This statistical analysis was not performed in the

intermediate PE group due to the low mortality rate among
those patients.
In the ROC curve analysis based on baseline HIF-1α and
troponin levels of patients with and without high-risk PE,
the areas under the curve were 83% and 84%, respectively.
At a baseline level of 0.81 ng/mL, HIF-1α had a sensitivity of
85% and specificity of 78% in detecting high-risk embolism.
Troponin showed sensitivity and specificity of 80% and 75%,
respectively, at a baseline level of 715.9 pg/mL (Figure 1).
The high-risk PE patients had a mean pulmonary arterial
pressure (systolic PAP) of 63.75 ± 16.37 mmHg and their
mean length of hospital stay was 11.31 ± 2.77 days. These
values were 52.5 ± 8.38 mmHg and 8.95 ± 2.54 days in the
intermediate high-risk PE group and 43.5 ± 6.91 mmHg
and 4.72 ± 1.63 days in the intermediate low-risk PE group,
respectively. Systolic PAP and length of hospital stay were
significantly greater in the high risk PE group compared to
the intermediate high-risk PE group (P = 0.03 and P = 0.05,
respectively) and in the intermediate high-risk PE group
compared to the intermediate low-risk PE group (P = 0.001
for both) (Table 1).
Baseline HIF-1α and troponin-I levels were moderately
correlated with systolic PAP in patients presenting with PE
(r = 0.553, P = 0.01; r = 0.521, P = 0.01). At 72-h follow-up,
these correlations were weaker but still significant (r = 0.21,
P = 0.01; r = 0.269, P = 0.01) (Figures 2 and 3).

Table 1. Comparison of the groups HIF-1 α, troponin-ı, ECHO and length of hospital stay
Control group
(mean ± SD)

Intermediate low risk PE
(mean ± SD)

Intermediate high risk PE High risk PE
(mean ± SD)
(mean±SD)

P*

0.46 ± 0.15*

0.65 ± 0.17*

0.95 ± 0.31*

1.35 ± 0.53*

0.001

0.47 ± 0.13

0.48 ± 0.27

0.41 ± 0.16

>0.05

16.7 ± 3.64*

801.9 ± 481.9*

1286.2 ± 714.2*

0.001

Troponin-ı 72 hours (pg/mL)

7.8 ± 5.6*

167.1 ± 155.1*

283.4 ± 249.9*

0.001

Systolic PAP (mm_Hg)

43.5 ± 6.91*

52.5 ± 8.38*

63.75 ± 16.37*

0.001

Length of stay (day)

4.72 ± 1.63*

8.95 ± 2.54*

11.31 ± 2.77*

0.001

HIF-1 α baseline (ng/mL)
HIF-1 α 72 hours (ng/mL)
Troponin-ı baseline (pg/mL)

10.2 ± 3.6*

P*: In the ANOVA between the groups, the average of high-risk PE group was significantly higher than the other groups.
Table 2. Comparison of baseline HIF-1α and troponin levels intermediate high-risk PE patient treatment groups and between surviving
and nonsurviving high-risk PE patients.
Intermediate high risk Intermediate high risk PE High risk PE High risk PE
PE DMAH treatment Thrombolytic treatment Survival (n:39) Non-survival (n:21) P*
(n:42) (mean ± SD)
(n:18) (mean ± SD)
(mean ± SD) (mean ± SD)
HIF-1 α baseline (ng/mL)

0.78 ± 0.11

Troponin-ı baseline (pg/mL) 776.2 ± 544.2

1.35 ± 0.28

0.98 ± 0.21

862.3 ± 293.5

1174.3 ± 649.2 1198.2 ± 802.2

1.52 ± 0.36

0.001/0.001
0.146/0.72

P*: Comparison between treatment groups/comparison of surviving and nonsurviving patients
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Figure 1. ROC curve analysis in patients with and without high-risk embolism
with HIF-1 α, troponin-ı baseline HIF-1 alpha: Hypoxia inducible factor-1α

Figure 2. Correlation between HIF-1 alpha baseline and systolic PAB PAB: Pulmonary
arterial pressure

4. Discussion
In this study, we observed that the HIF-1α levels of PE
patients increased with higher PE clinical risk stratification
in correlation with troponin-I level, one of the variables
included in clinical scoring. Patients that required
thrombolytic therapy or died had higher HIF-1α levels
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than other patients, whereas troponin-I values did not
differ significantly in these groups. Therefore, HIF-1α may
be a better prognostic marker than troponin-I.
The clinical presentations of PE are classified as high-,
intermediate-, and low-risk [8]. In acute intermediate-risk
PE patients, transthoracic ECHO is the most frequently
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Figure 3. Correlation between troponin-ı baseline and systolic PAB PAB: Pulmonary
arterial pressure

used method to evaluate right ventricular dysfunction.
Right ventricular dysfunction is defined using parameters
such as right ventricular dilation, hypokinesis of the
right ventricular wall, paradoxical movement of the
interventricular septum, tricuspid valve insufficiency,
increased pulmonary artery diameter, and higher ratio of
right ventricular diastolic end diameter to left ventricular
diastolic diameter [9,10].
Cardiac troponin T and I are enzymes specific to the
cardiac muscles. Right ventricular dilation that occurs
as a result of acute right heart failure due to high-risk
PE increases right ventricle oxygen demand. Troponin,
BNP, and NT-proBNP measurements may be useful
in distinguishing high- and intermediate-risk patients
from low-risk patients for prognostic evaluation. They
can also be used to further stratify intermediate-risk
patients into high-intermediate and low-intermediaterisk subgroups. However, it must be kept in mind that
these markers are also elevated in conditions such as
acute exacerbation of COPD, sepsis, acute kidney failure,
trauma, rhabdomyolysis, and congestive heart failure
[11,12]. Although cardiac biomarkers have an important
place in clinical risk scoring, the absence of a definite
cut-off value for the differentiation of high-risk and highintermediate-risk patients necessitates clinical observation
for thrombolytic therapy in the high-intermediate-risk
group. However, the time spent in clinical follow-up
sometimes works to the patient’s detriment, with hypoxic
respiratory failure and sudden hemodynamic collapse

resulting in a precipitous death. This led to the need to
investigate alternative biomarkers in clinical scoring.
The HIF1 gene, which is activated under hypoxic
conditions, functions by hydroxylating and activating
the proline hydroxylase α subunit. Primarily through
erythropoietin synthesis, HIF-1α prevents reoxygenation
injury via VEGF-mediated neovascularization, glycolytic
activity, and glutathione peroxidase. It activates enzymes
that prepare cells to withstand hypoxia.
In rat models of induced PE, HIF-1α mRNA expression
was detected in the pulmonary arterial wall. In contrast,
HIF-1α expression was not observed in samples of human
myocardial tissue from healthy individuals at the onset of
right ventricular hypertrophy but increased in correlation
with myocardial ischemia. In a rat model of induced
PE, HIF-1α level was found to increase with the onset of
disease, show rapid elevation until 72 h in the untreated
period, then increase at a slower rate until week 4 [13]. In
another study of recombinant adenovirus-mediated HIF1α in a rat model, it was observed that HIF-1α increased
VEGF-A level, which plays an important role in thrombus
organization and thrombolysis [14]. It was observed that
HIF-1α, the main inducer of VEGF synthesis, also plays an
important role in transmural angiogenesis in heart failure
in addition to the effects of VEGF on thrombi [15].
Based on the results of our study, we observed
significant differences in baseline levels of HIF-1α
and troponin-I between all groups. However, in the
intermediate-risk group, who were the main focus of
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this study, our observation of a significant difference in
baseline HIF-1α but not in troponin-I between the 18
patients who received thrombolytic therapy and the 42
patients who were followed with low-molecular-weight
heparin suggests that HIF-1α may be an important
criterion for implementing early reperfusion therapy in
this patient group. ROC curve analysis between HIF-1α
and troponin-I levels showed that although the sensitivity
and specificity of HIF-1α were relatively low, they were still
higher than those of troponin-I in the distinction of highrisk PE. Using the two tests together in the discrimination
of massive PE (with cut-off values of 0.81 ng/mL for HIF1α, and 715.9 pg/mL for troponin-I) resulted in 68%
sensitivity and 94% specificity. On the other hand, if a
test was considered positive, the sensitivity was 98% and
the specificity was 69%. Furthermore, the higher HIF-1α
levels among deceased patients compared to survivors of

PE might demonstrate the utility of this parameter as an
early indicator of poor prognosis.
Mortality in the present study was limited to 21
patients in the high-risk PE group and 9 patients in the
intermediate-high-risk PE, which may increase the margin
of error in the early recognition of poor prognosis. For this
reason, more extensive studies with larger patient groups
are needed.
In conclusion, HIF-1α may provide an early guide for
clinical risk stratification of PE and the administration
of thrombolytic therapy to early intermediate-high-risk
patients. Initial HIF-1α is a better predictor of mortality
than troponin level and thus may be a more useful
parameter in clinical follow-up.
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